ApoC-III mRNA Inhibitors
2 drugsAbout ApoC-III mRNA
Apolipoprotein C-III mRNA (ApoC-III mRNA) is a target for drug development. Its modulation offers a potential avenue for therapeutic intervention.
Currently, there is no genetic evidence directly linking ApoC-III mRNA to specific diseases. However, the existence of two FDA-approved drugs targeting it underscores its therapeutic potential.
Two FDA-approved drugs, REDEMPLO and TRYNGOLZA, target ApoC-III mRNA. These include one siRNA and one small molecule, developed by ARROWHEAD and IONIS PHARMS INC, respectively.
Top ApoC-III mRNA Drugs
ARROWHEAD and IONIS PHARMS INC are the only companies with approved drugs.
Limited competition suggests a potential opportunity for new market entrants.
ApoC-III mRNA Drug Modality Landscape
Modalities
Routes of Administration
ApoC-III mRNA is druggable by both biologics (1) and small molecules (1), indicating broad therapeutic accessibility.
Consider exploring alternative modalities to differentiate from existing therapies.
📈 Modality Evolution
Small molecules pioneered ApoC-III mRNA targeting (2024), with sirnas entering more recently (2025).
ApoC-III mRNA Clinical Trials 17 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ApoC-III mRNA. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 15 | 9 | 0 | 6 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ApoC-III mRNA Drug Approval Timeline (2024 - 2025)
The first drug was approved in 2024, with the most recent in 2025.
Recent approvals suggest growing interest, but it is too early to assess market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ApoC-III mRNA. A trial counts if an approved drug acting on ApoC-III mRNA is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.